Details of Disease

General Information of Disease (ID: DISJ9M77)

Disease Name Type 2 diabetes
Disease Class 5A11: Type 2 diabetes mellitus
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISJ9M77: Type 2 diabetes
ICD Code
ICD-11
ICD-11: 5A11
ICD-10
ICD-10: E08-E13
Disease Identifiers
MONDO ID
MONDO_0005148
MESH ID
D003924
UMLS CUI
C0011860
OMIM ID
125853
MedGen ID
41523
HPO ID
HP:0005978
SNOMED CT ID
44054006

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 3 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Bexagliflozin DMK56G0 Approved NA [1]
Linagliptin DMWFJTR Approved Small molecular drug [2]
Tirzepatide DMQNMAT Approved NA [3]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 38 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Orforglipron DMC50VB Phase 3 Small molecule [4]
PB-119 DM98PS6 Phase 3 NA [5]
BI 456906 DM1NMGJ Phase 2 Small molecular drug [6]
Bimagrumab DMH7Q4E Phase 2 Antibody [7]
CS02 DMK8F0H Phase 2 NA [8]
Epeleuton DMJ1YQ2 Phase 2 Small molecule [9]
GLY-200 DM89FXL Phase 2 NA [10]
IONIS-GCGR-Rx DMB4GD9 Phase 2 Antisense oligonucleotide [11]
LY3437943 DMN37M6 Phase 2 Peptide [12]
O-304 DMXM34I Phase 2 Small molecular drug [13]
Oxyntomodulin DM8YEDT Phase 2 Peptide [14]
PF-06882961 DM7EJ8S Phase 2 Small molecular drug [15]
PF-07081532 DM9WHMF Phase 2 Small molecule [16]
REMD 477 DM13OVF Phase 2 Antibody [17]
RGT-075 DM1OBHA Phase 2 NA [18]
TTP399 DMBKQSZ Phase 2 Small interfering RNA [19]
Vupanorsen DMN6J18 Phase 2 Antisense oligonucleotide [20]
ZGN-1061 DM9KB7A Phase 2 Small molecular drug [21]
AZD0186 DM57J20 Phase 1 Small molecule [22]
CPL207-280CA DMFMGZR Phase 1 Small molecular drug [23]
CT 868 DMI7XMU Phase 1 Small molecular drug [24]
CT-388 DMWHBE5 Phase 1 NA [25]
DA-1241 DMPJA64 Phase 1 Small molecular drug [26]
DACRA 089 DM5TB76 Phase 1 Peptide [27]
GZR18 DM4YR7H Phase 1 NA [28]
HTI-2088 DMNYU4L Phase 1 NA [29]
LX2761 DM8ZS7T Phase 1 Small molecular drug [30]
LY2922470 DMGLTE2 Phase 1 Small molecular drug [31]
LY3305677 DMJMLLW Phase 1 NA [32]
LY3457263 DM69JPL Phase 1 NA [33]
LY3493269 DM3Y5QZ Phase 1 NA [34]
LY3532226 DM9IZG3 Phase 1 NA [35]
LY3537021 DMJUXW7 Phase 1 NA [36]
MEDI7219 DM0SI61 Phase 1 NA [37]
NGM217 DMO7PBU Phase 1 NA [38]
OG2023SC DMZB7A6 Phase 1 NA [39]
SHR0534 DMGFTAI Phase 1 NA [40]
TAK-648 DMQ8YKR Phase 1 NA [41]
------------------------------------------------------------------------------------
⏷ Show the Full List of 38 Drug(s)
This Disease is Treated as An Indication in 3 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
BMS-986118 DM4BZEJ Preclinical Small molecular drug [42]
CNX-011-67 DM1H8D6 Preclinical Small molecular drug [23]
DS-1558 DMMI2EY Preclinical Small molecular drug [23]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 214373.
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 208026
3 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215866.
4 ClinicalTrials.gov (NCT05048719) A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
5 ClinicalTrials.gov (NCT04504396) A Multicenter, Randomized, Double-blinded, Placebo-controlled Trial Comparing the Efficacy and Safety of PB-119 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Alone. U.S.National Institutes of Health.
6 ClinicalTrials.gov (NCT04153929) A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.. U.S. National Institutes of Health.
7 ClinicalTrials.gov (NCT03005288) Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes. U.S. National Institutes of Health.
8 ClinicalTrials.gov (NCT03317028) A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone. U.S.National Institutes of Health.
9 ClinicalTrials.gov (NCT04365400) A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes. U.S.National Institutes of Health.
10 ClinicalTrials.gov (NCT05478525) A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients. U.S.National Institutes of Health.
11 Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
12 ClinicalTrials.gov (NCT04867785) A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes. U.S.National Institutes of Health.
13 Clinical pipeline report, company report or official report of Betagenon.
14 ClinicalTrials.gov (NCT03406377) Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects. U.S. National Institutes of Health.
15 ClinicalTrials.gov (NCT03985293) A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
16 ClinicalTrials.gov (NCT05579977) A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE RANGING, DOSE FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-07081532, AND OPEN LABEL ORAL SEMAGLUTIDE, IN ADULTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON METFORMIN, AND SEPARATELY PF-07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM. U.S.National Institutes of Health.
17 ClinicalTrials.gov (NCT02455011) Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
18 Clinical pipeline report, company report or official report of Regor Therapeutics
19 ClinicalTrials.gov (NCT02405260) Add Glucokinase Activator to Target A1c (AGATA). U.S. National Institutes of Health.
20 ClinicalTrials.gov (NCT03371355) Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease. U.S. National Institutes of Health.
21 ClinicalTrials.gov (NCT03254368) Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes. U.S. National Institutes of Health.
22 ClinicalTrials.gov (NCT05694741) A Phase 1 Randomized, Single-blind, Placebo-controlled, First-in-Human and Sequential Group Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186 Following Single Ascending Doses Via Oral Administration. U.S.National Institutes of Health.
23 Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75.
24 Clinical pipeline report, company report or official report of Carmot Therapeutics.
25 ClinicalTrials.gov (NCT04838405) A Phase 1 Randomized, Double Blind, Placebo Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-388 in Otherwise Healthy Overweight and Obese Adult Participants and in Obese Patients With Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
26 ClinicalTrials.gov (NCT03646721) A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM. U.S. National Institutes of Health.
27 ClinicalTrials.gov (NCT03907202) A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM. U.S. National Institutes of Health.
28 ClinicalTrials.gov (NCT05328726) A Double-blind, Randomized, Placebo-controlled, Sequential, Single, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Parameters of Subcutaneous Injections of GZR18 in Healthy Subjects. U.S.National Institutes of Health.
29 ClinicalTrials.gov (NCT03203811) A Phase 1, Study to Evaluate HTI-2088 Tablet. U.S. National Institutes of Health.
30 Clinical pipeline report, company report or official report of Lexicon Pharmaceuticals.
31 ClinicalTrials.gov (NCT01867216) A Study of Multiple Doses of LY2922470 in Participants With Diabetes. U.S. National Institutes of Health.
32 ClinicalTrials.gov (NCT03928379) A Multiple-Ascending Dose Study in Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677. U.S.National Institutes of Health.
33 ClinicalTrials.gov (NCT05377333) Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes. U.S.National Institutes of Health.
34 ClinicalTrials.gov (NCT04515576) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of LY3493269 in Patients With Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
35 ClinicalTrials.gov (NCT05407961) A Phase 1b, 2-Part, Investigator- and Participant-Blind, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3532226 in Participants With Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
36 ClinicalTrials.gov (NCT04586907) A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3537021 in Healthy Participants and Patients With Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
37 ClinicalTrials.gov (NCT03362593) A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses. U.S. National Institutes of Health.
38 Clinical pipeline report, company report or official report of NGM Biopharma
39 ClinicalTrials.gov (NCT03617081) First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.. U.S. National Institutes of Health.
40 ClinicalTrials.gov (NCT03006159) A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients. U.S. National Institutes of Health.
41 ClinicalTrials.gov (NCT02430870) TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
42 Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development. Expert Opin Investig Drugs. 2016 Aug;25(8):871-90.